TikTok's 'affordable' compounded GLP-1 claims, fact-checked

What did @haleighweaver5 actually say?

The creator is directing viewers to message her privately to get a link to a telehealth company selling compounded semaglutide and tirzepatide for weight loss. She describes a portal-based doctor interaction, a short intake assessment, and a three-month supply shipped directly to the patient. That is the full model: DM for a link, answer some questions, get three months of medication mailed to you.

To her credit, she does say there is a licensed doctor involved and that the process includes an assessment. She is not claiming you can get this with zero medical oversight. But the structure she describes — messaging a TikTok creator to access medication — raises real questions about how thorough that oversight actually is, and whether patients understand what they are receiving is not an FDA-approved branded drug.

Does the science back this up?

The underlying medications are real and well-studied. Semaglutide and tirzepatide are among the most effective pharmacological weight-loss interventions ever tested in clinical trials. The problem is not the drugs — it is the supply chain and the access model being described here.

Semaglutide (brand name Wegovy) produced an average of 14.9% body weight reduction over 68 weeks in the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine). Tirzepatide (brand name Zepbound) showed up to 20.9% weight reduction in the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine). These are legitimate, substantial results. Compounded versions of these drugs were legally permitted during the FDA shortage period, but that status has been changing. The FDA declared the Ozempic/Wegovy shortage resolved in early 2025, which puts compounded semaglutide in a legally murky position. Compounded tirzepatide remains under active FDA scrutiny.

What did they get wrong (or right)?

The creator gets partial credit for acknowledging a real doctor is involved. That is better than some of what circulates on this platform. But several things are either wrong or missing in ways that matter to patients.

First, she says you can get "three months at once" like it is a perk. For a drug class that requires dose titration and monitoring, receiving a large supply upfront without built-in check-ins is not a feature — it is a gap in care. The Endocrine Society and obesity medicine guidelines consistently recommend regular follow-up during GLP-1 therapy to manage side effects and adjust dosing.

Second, she never tells viewers these are compounded drugs, not brand-name FDA-approved products. Compounded drugs are not FDA-approved for safety, efficacy, or manufacturing quality. The FDA has issued multiple warnings about compounded GLP-1 products containing incorrect dosages or unapproved salt forms (FDA Safety Alert, 2024). Patients deserve to know that distinction before they order.

Third, routing access through a TikTok creator's DMs is not a standard or transparent care pathway. It is promotional marketing for a specific commercial vendor.

What should you actually know?

If you are considering compounded semaglutide or tirzepatide, the access model matters as much as the drug itself. Here is what legitimate telehealth care for GLP-1 medications should include: a thorough medical history review, not just "an assessment"; contraindication screening (these drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma); ongoing follow-up appointments, not just a one-time portal message; and clear disclosure that you are receiving a compounded product, not Ozempic, Wegovy, Mounjaro, or Zepbound.

The FDA's evolving enforcement posture on compounded GLP-1s also means the legal availability of these products through compounding pharmacies could change rapidly. Patients who start on compounded versions may face supply disruptions or need to transition to brand-name products, which have very different price points without insurance coverage.

Getting medication through a social media referral link is not inherently wrong, but it puts the burden on the patient to vet the provider, the pharmacy, and the product quality — most patients are not equipped to do that alone.